Royce & Associates LP Boosts Stock Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

Royce & Associates LP increased its holdings in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 65.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 697,001 shares of the biotechnology company's stock after purchasing an additional 276,432 shares during the period. Royce & Associates LP owned approximately 0.29% of ADMA Biologics worth $13,828,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Tsfg LLC bought a new stake in shares of ADMA Biologics in the 1st quarter worth about $51,000. Farther Finance Advisors LLC increased its stake in ADMA Biologics by 1,149.1% during the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 2,505 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in ADMA Biologics during the fourth quarter valued at approximately $85,000. CIBC Private Wealth Group LLC lifted its stake in shares of ADMA Biologics by 137.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after purchasing an additional 2,954 shares during the last quarter. Finally, Covestor Ltd boosted its holdings in shares of ADMA Biologics by 7,038.1% in the 4th quarter. Covestor Ltd now owns 5,996 shares of the biotechnology company's stock worth $103,000 after purchasing an additional 5,912 shares during the period. Institutional investors own 75.68% of the company's stock.

Insider Buying and Selling at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the transaction, the director directly owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve Elms sold 194,749 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the sale, the director owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 464,621 shares of company stock valued at $9,644,269 in the last three months. Company insiders own 3.50% of the company's stock.

ADMA Biologics Trading Up 4.0%

ADMA traded up $0.70 during trading hours on Friday, reaching $18.01. 3,276,489 shares of the company's stock traded hands, compared to its average volume of 2,444,680. The firm has a 50-day moving average price of $19.01 and a 200 day moving average price of $18.73. The firm has a market capitalization of $4.30 billion, a PE ratio of 21.19 and a beta of 0.43. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. ADMA Biologics Inc has a 52-week low of $10.21 and a 52-week high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The firm's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.08 earnings per share. As a group, sell-side analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ADMA shares. Raymond James Financial boosted their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.